Limits...
Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.

Yanik EL, Siddiqui K, Engels EA - Cancer Med (2015)

Bottom Line: Sirolimus use was associated with lower overall cancer incidence (incidence rate ratio [IRR] = 0.71, 95% CI = 0.56-0.90), driven by a reduction in incidence of nonmelanoma skin cancer (NMSC, IRR = 0.49, 95% CI = 0.32-0.76).The protective effect of sirolimus on NMSC risk was most notable in studies comparing sirolimus against cyclosporine (IRR = 0.19, 95% CI = 0.04-0.84).Sirolimus may also reduce kidney cancer risk but did not appear protective for other cancers, and it may actually increase prostate cancer risk.

View Article: PubMed Central - PubMed

Affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

No MeSH data available.


Related in: MedlinePlus

Flow chart of study selection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4567030&req=5

fig01: Flow chart of study selection.

Mentions: We identified 2246 articles matching our search terms in PubMed. Of these, 79 articles had titles or abstracts indicating that the study was possibly a RCT or observational study of sirolimus use in kidney recipients (Fig.1). After reviewing these articles, 34 were excluded because they did not compare sirolimus-exposed recipients to unexposed recipients. Thirty articles were excluded because no malignancies were identified in the study or because information on malignancies could not be obtained. In a secondary search of bibliographies and Web of Science, we identified seven additional studies that met our inclusion criteria (Fig.1). In the final meta-analysis, 22 studies were included, of which 20 were RCTs and two were observational studies (Table1).


Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.

Yanik EL, Siddiqui K, Engels EA - Cancer Med (2015)

Flow chart of study selection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4567030&req=5

fig01: Flow chart of study selection.
Mentions: We identified 2246 articles matching our search terms in PubMed. Of these, 79 articles had titles or abstracts indicating that the study was possibly a RCT or observational study of sirolimus use in kidney recipients (Fig.1). After reviewing these articles, 34 were excluded because they did not compare sirolimus-exposed recipients to unexposed recipients. Thirty articles were excluded because no malignancies were identified in the study or because information on malignancies could not be obtained. In a secondary search of bibliographies and Web of Science, we identified seven additional studies that met our inclusion criteria (Fig.1). In the final meta-analysis, 22 studies were included, of which 20 were RCTs and two were observational studies (Table1).

Bottom Line: Sirolimus use was associated with lower overall cancer incidence (incidence rate ratio [IRR] = 0.71, 95% CI = 0.56-0.90), driven by a reduction in incidence of nonmelanoma skin cancer (NMSC, IRR = 0.49, 95% CI = 0.32-0.76).The protective effect of sirolimus on NMSC risk was most notable in studies comparing sirolimus against cyclosporine (IRR = 0.19, 95% CI = 0.04-0.84).Sirolimus may also reduce kidney cancer risk but did not appear protective for other cancers, and it may actually increase prostate cancer risk.

View Article: PubMed Central - PubMed

Affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.

No MeSH data available.


Related in: MedlinePlus